Evidence for distinguishable treatment costs among paranoid schizophrenia and schizoaffective disorder

• Verfasst von: Hirjak, Dusan [VerfasserIn]
• Verfasst von: Hochlehnert, Achim [VerfasserIn]
• Verfasst von: Thomann, Philipp [VerfasserIn]
• Verfasst von: Kubera, Katharina Maria [VerfasserIn]
• Verfasst von: Schnell, Knut [VerfasserIn]
• Titel: Evidence for distinguishable treatment costs among paranoid schizophrenia and schizoaffective disorder
• Verf.angabe: Dusan Hirjak, Achim Hochlehnert, Philipp Arthur Thomann, Katharina Maria Kubera, Knut Schnell
• E-Jahr: 2016
• Jahr: July 8, 2016
• Umfang: 10 S.
• Fussnoten: Gesehen am 14.05.2020
• Titel Quelle: Enthalten in: PLOS ONE
• Ort Quelle: San Francisco, California, US : PLOS, 2006
• Jahr Quelle: 2016
• Band/Heft Quelle: 11(2016,7) Artikel-Nummer e0157635, 10 Seiten
• ISSN Quelle: 1932-6203
• DOI: doi:10.1371/journal.pone.0157635
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: Diagnostic medicine
• Sach-SW: Drug therapy
• Sach-SW: Finance
• Sach-SW: Germany
• Sach-SW: Health economics
• Sach-SW: Inpatients
• Sach-SW: Mental health and psychiatry
• Sach-SW: Schizophrenia
• K10plus-PPN: 1698246692

Abstract

Background Schizophrenia spectrum disorders result in enormous individual suffering and financial burden on patients and on society. In Germany, there are about 1,000,000 individuals suffering from schizophrenia (SZ) or schizoaffective disorder (SAD), a combination of psychotic and affective symptoms. Given the heterogeneous nature of these syndromes, one may assume that there is a difference in treatment costs among patients with paranoid SZ and SAD. However, the current the national system of cost accounting in psychiatry and psychosomatics in Germany assesses all schizophrenia spectrum disorders within one category. Methods The study comprised a retrospective audit of data from 118 patients diagnosed with paranoid SZ (F20.0) and 71 patients with SAD (F25). We used the mean total costs as well as partial cost, i.e., mean costs for medication products, mean personal costs and mean infrastructure costs from each patient for the statistical analysis. We tested for differences in the four variables between SZ and SAD patients using ANCOVA and confirmed the results with bootstrapping. Results SAD patients had a longer duration of stay than patients with SZ (p = .02). Mean total costs were significantly higher for SAD patients (p = .023). Further, we found a significant difference in mean personnel costs (p = .02) between patients with SZ and SAD. However, we found no significant differences in mean pharmaceutical costs (p = .12) but a marginal difference of mean infrastructure costs (p = .05) between SZ and SAD. We found neither a common decrease of costs over time nor a differential decrease in SZ and SAD. Conclusion We found evidence for a difference of case related costs of inpatient treatments for paranoid SZ and SAD. The differences in mean total costs seem to be primarily related to the mean personnel costs in patients with paranoid SZ and SAD rather than mean pharmaceutical costs, possibly due to higher personnel effort and infrastructure.